Related Experiment Videos
Neonatal technology, perinatal survival, social consequences, and the perinatal paradox
1Department of Pediatrics, Medical College of Wisconsin, Milwaukee 53226, USA.
Insights
While surfactant therapy improves outcomes for premature infants, the high rate of low birthweight persists. Focus should shift to preventing low birthweight to reduce long-term health risks and healthcare burdens.
Area of Science:
- Neonatal Medicine
- Public Health
- Pediatrics
Background:
- Exogenous surfactant therapy has significantly reduced mortality and complications in premature infants with respiratory distress syndrome.
- Despite therapeutic advances, the overall number of low-birthweight infants has not decreased, creating a vulnerable population requiring extensive care.
- Surviving low-birthweight infants face long-term risks including neurosensory impairment, cerebral palsy, chronic lung disease, and socioeconomic challenges linked to poverty.
Purpose of the Study:
- To highlight the ongoing challenge of high low-birthweight rates despite advancements in neonatal care.
- To advocate for a shift in focus from treating consequences to preventing low birthweight.
- To emphasize the need for population-based strategies to reduce the incidence of low birthweight.
Main Methods:
- This study is a review and analysis of existing data on infant mortality, prematurity, and low birthweight trends.
- It synthesizes information on the impact of surfactant therapy and associated long-term morbidities.
- It discusses the socioeconomic factors contributing to low birthweight and its consequences.
Main Results:
- Exogenous surfactant therapy has improved survival rates for premature infants but has not reduced the overall incidence of low birthweight.
- Low-birthweight infants, even with treatment, remain susceptible to significant short- and long-term health and developmental issues.
- The high prevalence of low birthweight strains healthcare resources and is closely associated with adverse social determinants of health.
Conclusions:
- Current therapeutic interventions, while crucial, do not address the root cause of premature birth complications.
- Preventing low birthweight through large-scale, population-based initiatives is essential for improving infant health outcomes and reducing healthcare system strain.
- A paradigm shift towards primary prevention of low birthweight is necessary to mitigate the long-term consequences for individuals and society.
Abstract:
Exogenous surfactant therapy for premature infants with respiratory distress syndrome has had a significant impact on infant mortality and on some complications of prematurity. Yet the total number of low-birthweight infants has not declined, resulting in a high-risk population who would require surfactant therapy and long-term child care. Surviving low-birthweight infants (despite surfactant therapy) remain at risk for the consequences of premature birth, such as neurosensory impairment, cerebral palsy, and chronic lung disease. In addition, because of the close association between poverty and low birthweight, surviving premature infants are at increased risk for the new morbidities such as violence, homelessness, child abuse and neglect, and addictive drug use. A goal should be to reduce the risk of being born with a low birthweight, rather than having to treat the consequences of premature gestation. Despite the marvelous advances that permit us to treat respiratory distress syndrome, the continuing high low-birthweight rate places a significant strain on our health care system. The goal should be redirected to identifying large population-based efforts to reduce the number of low-birthweight infants.